Events15 November 2008 - Rhenovia at Neuroscience 2008 Washington DC: 15-19 November
|
Walter E. Washington Convention Center
|
|
 |
| The
Walter E. Washington Convention Center in Washington, DC will host
Neuroscience 2008. More than 30,000 people are expected to attend. |
|
Neuroscience
2008, the Society for Neuroscience's 38th annual meeting, is scheduled
for Nov. 15 to 19 in Washington, DC. Each year SfN provides the premier
venue for neuroscientists to share research findings. By attending
lectures, symposia, and workshops, meeting attendees experience the
most exciting and cutting-edge research the field of neuroscience has
to offer.
 14 October 2008 - Rhenovia at MIPTEC Basel 14-16 October 2008
MipTec is the premier European conference and exhibition encompassing
innovative approaches to high quality science and technology for
efficient drug discovery. The mission of MipTec is to bring together
scientists from all disciplines involved in drug discovery within
pharmaceutical and biotech companies, academic labs and technology
providers in an atmosphere where ideas and experiences are shared and
discussed. This atmosphere is created through a scientific program
covering key topics and the latest breakthroughs in the diverse fields
that make up drug discovery. 1. Drug Discovery Technologies:S. Bischoff* (1), M. Faupel (1), J.M Bouteiller (2), R. Greget (1), T. Berger (2), M. Baudry (2) (1)Rhenovia Pharma (Mulhouse, FR); (2)Univ.Southern California, Rhenovia Pharma (Los Angeles, US) Modeling and Biosimulation of CNS Diseases: A novel technology for Drug Development Neurological as well as psychiatric disorders are extremely complex, multifactorial and dynamical diseases. These diseases are most probably of multiple origins and involve separately, independly or simultaneously different physiological functions, multiple pathways, and neuronal/gial connectivity. They might also affect dynamical features such as feedback-feedforward regulations, cross talk between cellular and intracellular mechanisms as well as the kinetic parameters of the interactions between the drugs used to treat them and their targets. For these reasons, the conventional drug discovery appproach that has been followed by the pharma industry over the last two decades might not be fully adequate to adress the multiple facets of these diseases. In particular, the single-target , single-mechanism approach so suited for high-throughput screening may not result in optimal identification of candidate therapeutics. We propose an alternative drug discovery strategy which takes into account most of these considerations: a) complexity, by developing a unique technology which allows to establish the pharmacological properties of a molecule based on its actions on physiological functions integrating their dynamic features; b) multiple facets of the diseases, by identifying most appropriate combinations of two or more drug principles providing synergistic pharmacological effects, and c) efficacy and safety, by decreasing risks of side effects. To this aim, we utilize a hybrid approach combining computer-assisted simulation of the molecular events taking place at excitatory glutamatergic synapses embedded into small neuronal networks and experimental validation. We propose that this approach will lead to the identification of the most appropriate targets to develop cognitive enhancers, and thereby the most suitable drug combinations with synergistics effects
1 October 2008 - Meet with Rhenovia at BioContact Quebec October 1-3, 2008
Rhenovia as a Presenter
BioContact Quebec 2008
will offer four presentation sessions (BLock I-IV). More than 150
biopharmaceutical companies, coming from Canada, the United States,
Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) Biopartnering
BioContact Quebec
2008 will make available private meeting rooms for one-on-one sessions.
These meetings will be offered in consecutive 30-minute periods. Senior
representatives from presenting biopharmaceutical companies and our
strategic partners will be on hand for biopartnering sessions Rhenovia as a Presenter
18 June 2008 - Rhenovia presents the EONS-RHENOMS platform at the 3rd Frontiers in Biomedical Devices Conference, a congress of the ASME, the American Society for Medical Engineering
EONS SYNAPTIC MODELING PLATFORM: EXPLORATION OF MECHANISMS REGULATING INFORMATION
PROCESSING IN THE CNS AND APPLICATION TO DRUG DISCOVERY
S. L. ALLAM1, J.-M. C. BOUTEILLER1,2,3, R. GREGET3, S. BISCHOFF3, M. BAUDRY2,3, T. W. BERGER1,2,3
1Dept. of Biomedical Engineering, 2Neuroscience., University of Southern California, Los Angeles, CA, 90089;
3Rhenovia Pharma, Mulhouse, France
Keywords: EONS, Synaptic, Synapse, Model, Simulation, Cluster, Node
ABSTRACT
EONS
modeling platform is a resourceful learning and research tool to study the
mechanisms underlying the non–linear dynamics of synaptic transmission with the
aid of mathematical models. Mathematical modeling of information processing in CNS
pathways, in particular modeling of molecular events and synaptic dynamics,
have not been extensively developed owing to the complex computations involved
in integrating a multitude of parameters. In this paper, we discuss the development
of a strategy to adapt the EONS synaptic modeling platform to a multi-node environment
using a parallel computational framework to compute data intensive long simulations
in a shorter time frame. We describe how this strategy can be applied to (i)
determine the optimal values of the numerous parameters required for fitting
experimental data, (ii) determine the impact of all parameters on various
aspects of synaptic transmission (under normal conditions or conditions
mimicking pathological conditions) and (iii) study the effects of exogenous
molecules on both healthy and pathological synaptic models.
|
4 June 2008 - Rhenovia at BioBAC Conference Basel
BioBac Basel Conference BioValley Investors Club and
BioValley Business Angels ClubAGENDA
11:30 Welcome, BioBAC Performance and next steps 11:40 Beyond Borders 2008 The Ernst & Young Global Biotech Report Jürg Zürcher, Partner Ernst & Young Basel 12.15 Snack and BioBAC members join in Company Presentations (20 min + 10 min discussion) 12.30 · II4SM, Basel Dr. Roland Haag, CEO Champion: Fritz R. Bühler 13.00 · Augurix, Lausanne Thierry Duvanel, CEO Champion:Jean-Pierre Rosfelder 13.30 · Rhenovia, Mulhouse Dr. Serge Bischoff, CEO Champion: Fritz R. Bühler14.15 End We look very much forward to meeting you again. With kind regards On behalf of the BioValley Investors Club and BioValley Business Angels Club Fritz R. Bühler
23 May 2008 - just marriedJust married , Jean Marie Bouteiller , our Plateforms Director and Christine
21 April 2008 - Rhenovia invited to Region Alsace
Adrien ZELLER
Président du Conseil Régional d'Alsace
conférence-débat
Financer l’innovation en Alsace
par l’Europe
dans le cadre de la Semaine de l’innovation
du 21 au 25 avril 2008,
organisée par l’Agence Régionale de l’Innovation
Lundi 21 avril 2008 de 14 h à 17 h 30
à la Maison de la Région
avec
Jean-Luc Dimarcq, directeur de l'incubateur SEMIA,
Marie Herth, Région Alsace, chef du service
Politiques Régionales Européennes.
"Depuis l’idée jusqu’au projet : aider les entreprises à
accéder aux financements européens du 7e PCRD
(Programme Cadre de Recherche et Développement
Technologique), une mission de l’Agence Régionale de
l'Innovation (ARI) soutenue par le FEDER"
Christophe Langlet, directeur régional adjoint d’OSEO Alsace,
Jean-Jacques Bernardini, chargé de mission Europe de l’ARI.
Avec l’éclairage de Michel Faupel,
Vice-Président de Rhenovia
un Débat avec la salle / questions-réponses
Synthèse des débats par Jean-François Evellin, Président de l’ARI
et Adrien Zeller
17 April 2008 - Participation of Rhenovia: April 17, 2008, 3rd Leadership Course: European Course for Life Sciences Executives
Date :
Thursday, April 17, 2008
- Saturday, April 19, 2008
Time :
Location : Hotel Bildungszentrum 21, Basel, close to University Hospital Basel
|
 |
 |
|
| |
|
|
Thursday, April 17, 2008
Hotel Bildungszentrum 21, Basel, close to University Hospital Basel
3rd Leadership Course: European Course for Life Sciences Executives
12 March 2008 - Rhenovia at BioSquare Basel 2008
 BioSquare 2008
During the past 7 years, BioSquare has become the most attended biotech partnering conference taking place in the first half of the year.
BioSquare
strengths rely mainly on its very high quality of participants. Indeed,
top business executives from biotech, Business developers from large
corporations as well as high ranking financiers gather at BioSquare to
make business.
The three-day event features a full program including panels and workshops led by corporate executives and biotech experts.
BioSquare 2008www.biosquare.com Biotechnology Conference Basel (CH) - March 12-14, 2008
9 October 2007 - Colloque ECRIN PARIS: Vers une standardisation en biologie : Enjeux scientifiques et économiques
Cette manifestation fait le point sur les enjeux et les perspectives de la standardisation en biologie
Quel rôle jouer ? Acteur ? Pionnier ?
Comment s’y prendre ? Programme
13h45, Accueil
Ouverture
à 14h00, par Danièle Auffray, Maire-adjointe chargée de la Recherche et des nouvelles technologies
Standards pour la biologie systémique : des données aux connaissances à 14h05, par Magali Roux, Laboratoire d’informatique de Paris VI-CNRS (LIP6)
Enjeux scientifiques et économiques
Principes de la biologie des systèmes illustrés par des modèles informatiques à 14h15, par Denis Noble, Université d’Oxford (GB)
Physiologie intégrative et nouvelles technologies des systèmes biologiques à 15h00, par Michel Faupel,Serge Bischoff, Rhenovia Pharma
Physiologie intégrative et innovation thérapeutique à 15h45, par Emmanuel Canet, Servier
Positionnement de la France dans l’Europe innovante : Biologie à grande échelle et exploitation des connaissances à 16h45, par Pierre Legrain, Institut de biologie et de technologies de Saclay, CEA
Politique d’innovation : quelle place donner au développement de standards en biologie
17h15, Table ronde Mar, 09/10/2007 - 12:00
Hôtel de Ville
Paris |
)
)
)
)
)
